Agios’s $345 Million Repurchase Agreement With Bristol-Myers Squibb Company

Wachtell, Lipton, Rosen & Katz advised Agios Pharmaceuticals on the deal.

Agios Pharmaceuticals, Inc. entered into a Share Repurchase Agreement with Bristol-Myers Squibb Company, pursuant to which Agios agreed to repurchase an aggregate of 7,121,658 shares of its common stock, par value $0.001 per share, held by certain subsidiaries of BMS for $48.3785 per share, for an aggregate purchase price of $344,535,310.

Agios Pharmaceuticals Inc. is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway.

Wachtell, Lipton, Rosen & Katz advised Agios Pharmaceuticals with Steven A. Cohen (Picture) and David K. Lam.

Involved fees earner: Steven Cohen – Wachtell, Lipton, Rosen & Katz; David Lam – Wachtell, Lipton, Rosen & Katz;

Law Firms: Wachtell, Lipton, Rosen & Katz;

Clients: Agios Pharmaceuticals;

Martina Bellini

Author: Martina Bellini